Purpose: The optimal dose of albuterol to use in the treatment of acute ast
hma has yet to be established. The National Asthma Education and Prevention
Program (NAEPP) recommends a starting dose of 2.5 to 5 mg of aerosolized a
lbuterol every 20 min, although European authorities recommend higher doses
. The pm-pose of this study was to compare 2.5 vs 7.5 mg of nebulized albut
erol for the treatment of acute asthma,
Subjects: We studied 160 patients presenting to the emergency department wi
th acute asthma,
Methods: On enrollment, patients underwent baseline testing, including init
ial spirometry. AU patients received prednisone, 60 mg, orally. Patients th
en received in a randomized, double-blinded fashion, nebulized albuterol ei
ther 2.5 or 7.5 mg every 20 min for a total of three doses. Spirometry was
repeated after each of the fn-st two treatments and again 40 min after comp
letion of the three treatments,
Results: The pretreatment FEV, was 36.9 +/- 16.6% of predicted normal in th
e low-close group vs 41.5 +/- 15.4% of predicted normal in the high-dose gr
oup (not significant [NS]), The patients in the low-dose group had a 50.3 /- 62.6% improvement in FEV1 pretreatment to post-treatment, whereas these
in the high-dose group had a 44.6 +/- 48.2% improvement in FEV1 (NS). There
was no difference in the admission rate in the low-dose group (43%) as com
pared with that of the high-dose group (39%; NS),
Conclusion: We conclude that there is no advantage to the routine administr
ation of doses of albuterol higher than 2.5 mg every 20 min. It is possible
that there mn,. be an advantage in the most severely obstructed patients,
although this study did not enroll enough patients with very severe asthma
to evaluate this, rls has been previously demonstrated, patients who subseq
uently require admission hale a diminished response to albuterol, This decr
eased responsiveness is seen with the first aerosol administration and is u
naffected by increasing the dose.